pharma · Scabies · Bioequivalence trial in healthy volunteers
Alphapharm
Alphapharm Pty Ltd
Alphapharm clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point, NSW 2000, AU
- Founded
- 1982
- Employees
- 187
- Programs
- 30
- Drugs
- 235
- Patents
- 12
Alphapharm projects
10 ClinicalTrials.gov programs sponsored by Alphapharm.
Alphapharm has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
19-02/MPA-S
Alphapharm Pty Ltd
Mild to moderate atopic dermatitis
1 trial -
974/24
Alphapharm Pty Ltd
Bioequivalence study in healthy volunteers under fasting conditions
1 trial -
CLP22001
Alphapharm Pty Ltd
Bioequivalence trial in healthy volunteers
1 trial -
CLP24001
Alphapharm Pty Ltd
Bioequivalence trial in healthy volunteers
1 trial -
Debio 0123-102
Alphapharm Pty Ltd
Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection
1 trial -
Debio 0123-106
Alphapharm Pty Ltd
Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene
1 trial -
Debio 0123-SCLC-104
Alphapharm Pty Ltd
Small cell lung cancer
1 trial -
Debio 1453-101
Alphapharm Pty Ltd
Sexual Transmitted Infection (STI)
1 trial -
Debio0123-101
Alphapharm Pty Ltd
Patients with tumors
1 trial -
TPT0301-001
Alphapharm Pty Ltd
adjunctive neuropathic pain
1 trial
Frequently asked questions
How many clinical projects does Alphapharm have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.